Clinical Trials News

BOSTON & SHANGHAI--(BUSINESS WIRE)--Eccogene Announces First Patient Enrolled in MOSAIC Phase 2a Trial Evaluating ECC4703 and ECC0509 for the Treatment of MASH...

MILAN & SAN MATEO, Calif.--(BUSINESS WIRE)--Dompé advances a novel, dual-inhibitor into Phase 3 for AKC, a chronic inflammatory eye disease with no FDA-approved treatment options....

HANGZHOU, China--(BUSINESS WIRE)--Atom now has a strategic foothold in dual therapeutic areas of metabolism and cardiovascular diseases, strengthening its core competitive edge....

MUNICH--(BUSINESS WIRE)--Tubulis today announced that its CEO and Co-founder Dominik Schumacher will present a company overview and update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Monday, January 12, 2026, at 3:00 pm PT in the Mission Bay Room (32nd Floor) at The Westin St. Francis. About Tubulis Tubulis generates uniquely matched antibody-drug conjugates with superior biophysical properties that have demonstrated durable on-tumo...

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma appoints Marika Murto to lead Global Product Strategy...

BOSTON--(BUSINESS WIRE)--Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA ap...

OSLO, Norway & BOSTON--(BUSINESS WIRE)--Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced that Gijs van den Brink, MD, PhD, has been appointed as an independent director to the company’s Board of Directors. Dr. van den Brink is a highly accomplished researcher and drug developer, having led immunology research and clinical development at both Roche and GSK. “Gijs brings an exceptional blend...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced it has entered into a 15-year contract including an option to renew with the UK Nuclear Decommissioning Authority (NDA) for access to up to 400 tonnes of reprocessed uranium (RepU). RepU continually regenerates providing a potentially sustainable s...

SINGAPORE--(BUSINESS WIRE)--Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stabi...

SHANGHAI & NEW YORK--(BUSINESS WIRE)--Shanghai Scizeng Medical Technology Co., LTD, a subsidiary of Changchun GeneScience Pharmaceutical Co., Ltd. (“GenSci”), RTW Investments, LP (“RTW”), and Yarrow Bioscience, Inc. (“Yarrow”) today announced an exclusive global ex-China license agreement for GS-098, a clinical-stage, first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves’ disease (GD) and thyroid eye disease (TED). Fo...